AZ buys back rights to Crohn's candidate from Allergan, ahea...

Allergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy regulators ahead of its merger with AbbVie.

FDA approves Allergan's migraine tablet ahead of AbbVie merg...

Allergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with or without aura.

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

Amgen, Allergan join Rituxan biosimilar challenge with FDA f...

Allergan builds case for migraine drug ubrogepant as FDA ver...

Allergan bolsters aesthetics pipeline with Exicure hair loss...